Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says its cancer treatment Cyramza improved progression-free survival for patients with a certain type of bladder cancer in a Phase II study. Also today, the drugmaker announced it had reached a settlement agreement with France-based pharmaceutical company Sanofi over the rights to an insulin product.
Lilly says Cyramza met its primary endpoint in the study involving patients with metastatic urothelial carcinoma who failed previous therapy. The company says, based on the findings, it has launched a Phase III trial. Yale University Cancer Center Professor of Medicine Daniel Petrylak says he is encouraged by the findings because people with advanced urothelial carcinoma currently have limited treatment options.
The settlement with Sonafi involves the insulin product Basaglar. The agreement allows Lilly and partner Boehringer Ingelheim to launch the product in the United States in December. The settlement grants Lilly a royalty-bearing license to manufacture and sell Basaglar in the Kwikpen device. The Food and Drug Administration tentatively approved the product last year. Lilly says it will now request final approval.